Cognition Therapeutics (NASDAQ:CGTX) Receives “Buy” Rating from Chardan Capital

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $11.00 target price on the stock.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright raised their target price on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. Finally, B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $1.00 to $1.50 in a research report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $8.30.

Cognition Therapeutics Stock Performance

Shares of Cognition Therapeutics stock traded down $0.02 during midday trading on Wednesday, reaching $0.50. 41,530,448 shares of the company’s stock traded hands, compared to its average volume of 2,132,587. The stock has a 50 day moving average of $0.69 and a 200-day moving average of $0.58. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95. The company has a market cap of $20.57 million, a PE ratio of -0.51 and a beta of 0.96.

Hedge Funds Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CGTX. BIOS Capital Management LP bought a new stake in Cognition Therapeutics during the 4th quarter valued at about $4,208,000. Sigma Planning Corp grew its holdings in shares of Cognition Therapeutics by 211.6% during the fourth quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after buying an additional 417,300 shares during the last quarter. Voss Capital LP bought a new stake in shares of Cognition Therapeutics during the fourth quarter valued at approximately $351,000. Geode Capital Management LLC raised its holdings in Cognition Therapeutics by 8.9% in the 4th quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after acquiring an additional 28,705 shares during the last quarter. Finally, Virtu Financial LLC lifted its position in Cognition Therapeutics by 40.1% in the 4th quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock valued at $56,000 after acquiring an additional 22,949 shares in the last quarter. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.